Piper Sandler Initiates Coverage On Edgewise Therapeutics with Overweight Rating, Announces Price Target of $48
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics (EWTX) with an Overweight rating and a price target of $48.
March 07, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler initiated coverage on Edgewise Therapeutics with an Overweight rating and set a price target of $48.
The initiation of coverage by Piper Sandler with an Overweight rating and a high price target suggests a positive outlook for Edgewise Therapeutics. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100